Portal Hypertension and Varices in Cirrhosis — Risk Stratification and Management

Key Numbers from This Guidance

This AASLD Practice Guidance updates the 2017 guidance on portal hypertension (PH) and gastroesophageal varices in cirrhosis, incorporating expert review of key randomized trials and the 2021 Baveno VII consensus. ref 1 The three major changes from the previous version are: formal recognition of compensated advanced chronic liver disease (cACLD) as a staging concept, noninvasive methods to identify clinically significant portal hypertension (CSPH), and a shift toward early beta-blocker initiation when CSPH is detected to prevent decompensation. ref 1

Understanding Portal Hypertension and Cirrhosis Stages

In a healthy liver, the portocaval pressure gradient (measured as the hepatic venous pressure gradient, or HVPG) ranges from 1 to 5 mm Hg. ref 2 Portal hypertension is defined as a gradient greater than 5 mm Hg — the point where resistance to blood flow through the scarred liver begins to push fluid backward into the portal system. ref 2 By far the most common cause is cirrhosis, which causes both structural scarring and a dynamic narrowing of liver blood vessels that accounts for roughly 30% of total resistance. ref 7 Portal hypertension can also have causes outside the liver itself — classified as prehepatic (such as portal vein thrombosis), intrahepatic (cirrhosis being the most common), or posthepatic (such as Budd-Chiari syndrome). ref 6

Cirrhosis has two broad clinical stages. In compensated cirrhosis, the liver maintains enough function that no major complications have occurred; median survival exceeds 12 years. ref 4 Once a patient develops decompensation — defined as overt ascites, variceal hemorrhage, or hepatic encephalopathy ref 3 — median survival falls to less than 1.5 years. ref 4 This dramatic shift in prognosis is why identifying and treating CSPH before decompensation occurs is the central goal of this guidance.

Within compensated cirrhosis, patients are further divided by whether they have CSPH (HVPG ≥10 mm Hg). ref 5 This sub-classification drives treatment decisions: only patients with proven or likely CSPH benefit from beta-blocker therapy to reduce decompensation risk. Once decompensation occurs and is followed by successive complications (recurrent hemorrhage, refractory ascites, hepatorenal syndrome), the patient enters "further decompensation" — a stage associated with much higher mortality.

Diagnosing CSPH Without Invasive Testing

Direct measurement of HVPG remains the gold standard for assessing portal pressure, ref 10 but it requires a specialized catheter procedure not widely available in most clinics. Fortunately, the combination of liver stiffness by transient elastography (see more on elastography) and platelet count is the best-validated noninvasive approach and is what this guidance recommends for routine clinical use.

Step 1: Rule Out or Rule In cACLD

Before assessing CSPH, the first question is whether the patient even has advanced chronic liver disease. Liver stiffness below 10 kPa by FibroScan rules out cACLD; 15 kPa or above rules it in. ref 11 Values between 10 and 15 kPa are indeterminate and require clinical judgment. The same question can be answered using MRE: values below 3.5 kPa rule out cACLD and 5.0 kPa or above rules it in. ref 17

Step 2: Identify CSPH Using the "Rule of Five"

For patients with confirmed or likely cACLD, CSPH is assessed using liver stiffness and platelet count together — the so-called "Rule of Five." ref 12 CSPH can be excluded when FibroScan is below 15 kPa and platelets are above 150 K/mm³. ref 13

An important caution: the positive predictive value of liver stiffness ≥25 kPa for CSPH is above 90% in non-obese patients with viral hepatitis or alcohol-related liver disease — but drops to only 63% in patients with obesity and NASH. ref 14 Additional evaluation is warranted in those patients. The liver stiffness-spleen size-to-platelet ratio score is another surrogate, with values above 2.65 corresponding to a CSPH risk above 80%. ref 15 Point shear wave elastography (pSWE) may also help: a cutoff above 2.17 m/s has been identified as potentially useful for detecting CSPH. ref 18

Avoiding Endoscopy with Baveno VI Criteria

Patients with liver stiffness below 20 kPa AND platelet count above 150 K/mm³ (the Baveno VI criteria) are very unlikely to have high-risk varices needing treatment — screening endoscopy can be safely avoided in this group. ref 21 Annual reassessment of liver stiffness and platelets is recommended for patients in cACLD without baseline CSPH. ref 19 Separately, spleen stiffness ≤46 kPa by FibroScan may also rule out varices needing treatment in patients who would otherwise meet Baveno VI criteria for screening endoscopy. ref 16

Who Should Get Beta-Blocker Therapy?

The most significant paradigm shift in this guidance is the recommendation to start beta-blocker therapy earlier — at the stage of compensated cirrhosis with CSPH — rather than waiting until varices are found on endoscopy. This is supported by the landmark PREDESCI trial: 201 patients with compensated cirrhosis and CSPH (confirmed by HVPG) were randomized to a beta-blocker or placebo. After 2 years, the beta-blocker group had a significantly lower risk of decompensation (HR 0.51; 95% CI, 0.26–0.97), mostly driven by lower rates of ascites. ref 23

To put the risk in perspective: among patients with compensated cirrhosis who have never bled, about 25% have varices on their first screening endoscopy. New varices develop at 4.4–5% per year, small varices progress to large ones in 10–20% of patients within 1–2 years, and annual bleeding from large varices is roughly 15%. ref 25 These numbers underscore why early intervention with beta-blockers — before varices even form — can make such a difference.

Which Beta-Blocker?

Carvedilol is the preferred NSBB (nonselective beta-blocker) for portal hypertension. Unlike propranolol and nadolol, carvedilol also has anti-alpha-adrenergic activity that relaxes intrahepatic blood vessels, producing a significantly greater reduction in HVPG. ref 8 Start at 6.25 mg once daily; increase to 12.5 mg/day after 2–3 days if tolerated. Down-titrate to 6.25 mg/day if systolic blood pressure falls below 90 mm Hg. ref 9 Unlike propranolol, there is no heart rate target for carvedilol — the only goal is to keep blood pressure ≥90 mm Hg.

The survival benefit of carvedilol over endoscopic band ligation (EVL) alone is striking: one long-term follow-up study found median survival of 7.8 years with carvedilol versus 4.2 years with EVL in patients with high-risk varices. ref 32 In patients with decompensated cirrhosis who have high-risk varices plus ascites, carvedilol was associated with improved survival (HR 0.41) in a prospective study. ref 31

NSBB Therapy and Endoscopy Screening

An important practical point: patients with cACLD and CSPH who are started on NSBBs do not require further screening endoscopy. Because beta-blocker therapy addresses the very indication for variceal screening, the endoscopy becomes redundant. ref 26

NSBBs in Patients with Ascites

Beta-blockers are generally safe in patients with ascites — including those with refractory ascites. However, patients with persistent systolic blood pressure below 90 mm Hg may not benefit to the same degree; there is concern that in this setting, NSBBs could attenuate the survival advantage and potentially increase the risk of hepatorenal syndrome. ref 33

When Are Beta-Blockers NOT Indicated?

Beta-blockers are explicitly not recommended for patients with cirrhosis who do not yet have CSPH — this was previously called "pre-primary prophylaxis." Trials have confirmed that NSBBs do not reduce the incidence of new varices, variceal bleeding, or decompensation at this early stage. ref 22 For patients with CSPH who cannot take NSBBs, endoscopic surveillance is recommended every 2 years when liver disease is active, or every 3 years when under control. ref 27 High-risk varices in NSBB-ineligible patients should be treated with primary prophylaxis EVL. ref 28

Patients with decompensated cirrhosis who are not currently on NSBBs and have never experienced variceal bleeding should undergo annual endoscopic screening to check for varices requiring treatment. ref 35

Acute Variceal Hemorrhage: Emergency Management

Acute variceal hemorrhage (AVH) remains one of the most dangerous complications of cirrhosis. Despite improvements in treatment, 6-week mortality still ranges from 10% to 15%. ref 36 The management is time-critical and involves simultaneous use of several interventions.

Immediate Steps (First Hour)

All patients with known or suspected cirrhosis presenting with gastrointestinal bleeding should be treated as having a portal hypertensive source until proven otherwise. Two actions must happen simultaneously at arrival: start a vasoactive drug (octreotide, somatostatin, or terlipressin where available) and start IV antibiotics. ref 37 Vasoactive therapy is continued for 2–5 days. ref 38

The preferred antibiotic is ceftriaxone 1 g IV every 24 hours, due to high rates of quinolone resistance in most centers, given for up to 5 days. ref 39 IV erythromycin 125–250 mg given 30–120 minutes before endoscopy improves visualization of the bleeding source. ref 43

Transfusion Strategy

Packed red blood cell transfusions should target a hemoglobin of approximately 7 g/dL. ref 40 This guidance is explicit: fresh frozen plasma (FFP) and platelet transfusions should NOT be administered based on INR or platelet count targets. There is no evidence of benefit for FFP in this setting, and evidence of potential harm. ref 40

Endoscopy Within 12 Hours

Upper endoscopy must be performed within 12 hours of presentation to identify and treat the bleeding source. ref 41 Endoscopic variceal ligation (EVL) is the standard approach for esophageal varices. After the initial session, EVL is repeated every 2–4 weeks until all varices are obliterated, followed by endoscopy at 6 months and then every 12 months to check for reappearance. ref 29 ref 42 Proton pump inhibitors should be discontinued once AVH is confirmed (in the absence of other specific indications), because ongoing use increases infection and encephalopathy risk. ref 46 Enteral feeding should restart as soon as the acute bleed is controlled. ref 47

Preemptive TIPS for High-Risk Patients

Not all variceal bleeders need TIPS. But for patients at highest risk — defined as CTP class B score >7 with active bleeding on endoscopy, or CTP class C score 10–13 — preemptive TIPS significantly improves outcomes. ref 44 This procedure should be placed within 72 hours, ideally within 24 hours of initial endoscopy. ref 44 Most (but not all) studies show it improves both bleeding control and survival. ref 45 Salvage TIPS — used when medical therapy and endoscopy fail — achieves hemostasis in over 90% of cases in non-prehepatic PH. ref 58

Preventing Rebleeding After a First Bleed

Without prophylaxis, up to 60% of patients rebleed within 1 year of a first variceal hemorrhage. ref 48 Secondary prophylaxis must be started within 7 days of the index bleed — the first 6 weeks carry the highest rebleeding risk. ref 49

The Gold Standard: NSBB + EVL

Combination therapy with a nonselective beta-blocker plus endoscopic variceal ligation (EVL) is the standard of care. Compared with EVL alone, this combination reduces rebleeding in all categories of patients and improves survival specifically in those with CTP class B and C cirrhosis. ref 50 Carvedilol, propranolol, and nadolol may all be used for secondary prophylaxis, but carvedilol produces greater HVPG reduction. EVL sessions are repeated every 2–4 weeks until variceal obliteration, with follow-up endoscopy at 6 months and then annually. ref 29

The Role of Statins

In a single double-anonymized RCT, adding simvastatin to standard secondary prophylaxis (NSBB + EVL) reduced mortality in patients surviving an episode of AVH. ref 51 This finding awaits confirmation in additional trials, but at least four prospective RCTs with statins in compensated cirrhosis are currently ongoing. ref 67 If simvastatin is used in decompensated cirrhosis (CTP B–C), it must not exceed 10–20 mg/day due to rhabdomyolysis risk. ref 51

TIPS for Secondary Prophylaxis

TIPS as first-line secondary prophylaxis achieves lower rebleeding rates than EVL + NSBB, but it does not improve survival and is associated with significantly higher rates of hepatic encephalopathy. ref 52 TIPS is therefore reserved for patients who rebleed despite adequate secondary prophylaxis, or for those with additional TIPS indications such as refractory ascites.

Gastric and Ectopic Varices

Gastric varices occur in 17–25% of patients with cirrhosis who have not yet bled. ref 53 The most clinically important types are cardiofundal varices (GOV2 along the greater curvature, and IGV1 in the fundus), which bleed at rates of 16–45% over 3 years — higher than esophageal varices — and are associated with greater treatment failure and mortality. ref 53 When gastric varices are identified, contrast-enhanced CT or MRI should be performed to rule out portal or splenic vein thrombosis, which often underlies their formation. ref 54

Acute Gastric Variceal Bleeding

Initial management follows the same principles as esophageal variceal bleeding: vasoactive therapy, antibiotics, conservative transfusion strategy, and endoscopy within 12 hours. For gastric varices, endoscopic cyanoacrylate injection (ECI or "glue injection") is the primary endoscopic approach, achieving hemostasis in 87–100% of cases — superior to band ligation. ref 55

When endoscopy or glue therapy fails, interventional options include TIPS and retrograde transvenous obliteration (BRTO and related techniques). The choice between them is individualized: TIPS is preferred in patients with preserved liver function (MELDNa below 20), large esophageal varices, or significant ascites. BRTO is preferred when hepatic encephalopathy is present or MELDNa above 20. ref 56

Preventing Gastric Variceal Rebleeding

After initial obliteration with ECI, an RCT of 64 patients found BRTO achieved lower rebleeding rates, fewer hospitalizations, and lower cost compared with repeat ECI. ref 57 Patients undergoing BRTO also had significantly less hepatic encephalopathy than those treated with TIPS. ref 57 NSBBs should be added to reduce portal pressure alongside any local endoscopic or endovascular therapy.

Portal Hypertensive Gastropathy (PHG)

Portal hypertensive gastropathy (PHG) is a "snakeskin" mosaic pattern of the stomach lining caused by elevated portal pressure and submucosal vascular congestion. It is extremely common, affecting 49–80% of patients with compensated cirrhosis — and 80–97% of those with medium or large varices. Patients without varices have a much lower prevalence of only 11%. ref 59

Most cases of PHG do not cause overt bleeding. Acute hemorrhage from PHG is uncommon, occurring in only 2.5–5% of cases. ref 60 However, chronic slow blood loss — defined as a ≥2 g/dL drop in hemoglobin over 6 months — is more common, affecting 4–12% of patients, and can cause iron-deficiency anemia over time. ref 60

For acute PHG bleeding, vasoactive therapy (octreotide, somatostatin, or terlipressin) at doses used for variceal bleeding is recommended for 2–5 days. ref 66 For prevention of recurrent PHG bleeding, NSBBs (propranolol or carvedilol) are recommended — a single RCT showed clear benefit of propranolol for preventing recurrent PHG hemorrhage. ref 61 If bleeding becomes transfusion-dependent despite optimal NSBB therapy, TIPS should be considered. ref 62

Related on LiverDecoded

Frequently Asked Questions